奥浦迈(688293) - 2025 Q4 - 年度业绩

Financial Performance - In 2025, the company achieved total operating revenue of CNY 354.91 million, a 19.40% increase compared to CNY 297.24 million in the previous year[4] - The net profit attributable to the parent company reached CNY 41.70 million, marking a significant increase of 98.07% from CNY 21.05 million year-on-year[4] - The net profit attributable to the parent company after deducting non-recurring gains and losses was CNY 20.85 million, reflecting a substantial increase of 216.57% compared to CNY 6.59 million in the previous year[4] - The company reported a basic earnings per share of CNY 0.37, which is a 94.74% increase from CNY 0.19 in the previous year[4] Assets and Equity - The company's total assets at the end of the reporting period were CNY 2,246.62 million, a decrease of 1.73% from the beginning of the period[5] - The company's equity attributable to the parent company increased by 0.18% to CNY 2,100.47 million compared to the beginning of the period[5] Taxation and Corporate Status - The company successfully recognized as a high-tech enterprise, reducing the corporate income tax rate from 25% to 15%, resulting in a tax expense reduction of approximately CNY 11 million[9] Business Segments Performance - The product business segment achieved a sales revenue growth of 23.03%, driven by deepening relationships with key clients and expanding market efforts[7] - The CDMO service segment faced challenges but still achieved slight revenue growth, demonstrating resilience amid market pressures[8] Development Pipeline - The company has 327 confirmed drug development pipelines utilizing its cell culture products, an increase of 80 from the end of 2024, indicating strong market recognition[8]